Abbott Laboratories (ABT)

Portfolio Grader currently ranks ABT as a Buy. This analytical tool evaluates stocks by employing proprietary fundamental and quantitative analytical. This represents no change from the previous week and is the same ranking ABT has had from Portfolio Grader for 4 months.

The current recommendation of Buy for Abbott Laboratories (NYSE:ABT) has been derived by using Louis Navellier's investing methods and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking ABT has had from Portfolio Grader for 3 months.

As one of the 782 companies in the GICS Health Care sector Abbott Laboratories (NYSE:ABT) is a constituent of the 161 company Health Care Equipment & Supplies GICS industry group within this sector. The market value of ABT is $97.4 billion which falls in the top 10% of its industry group. Currently, the stock's Portfolio Grader ranking places it 30 among the 161 companies in this industry group, giving it a well above-average position; in the top quartile of the sector with a ranking of 101 among the 782 companies in the sector, and number 593 in the nearly 5,000 company Portfolio Grader universe.

The current recommendation of Buy for Abbott Laboratories (NYSE:ABT) is derived using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing methodology. This represents no change from the previous week and is the same ranking ABT has had from Portfolio Grader for 2 months.

Abbott Laboratories (NYSE:ABT) is a member of the 161 company Health Care Equipment & Supplies GICS industry group, which is a segment of the 781 company GICS Health Care sector. ABT has a market value of $96.7 billion which is in the top 10% of its industry group. Portfolio Grader's current ranking for ABT puts it 31 among the 161 companies in this industry group, putting in the top quartile; in the top quartile of the sector with a ranking of 95 among the 781 companies in the sector, and number 606 in the nearly 5,000 company Portfolio Grader universe.

Currently, Abbott Laboratories (NYSE:ABT) has a Buy using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing methodology. The current Portfolio Grader recommendation on the shares has been in place for 2 months.

Abbott Laboratories (NYSE:ABT) is ranked as a Buy using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing system. This represents no change from the previous week and is the same ranking ABT has had from Portfolio Grader for 2 months.

The current recommendation of Buy for Abbott Laboratories (NYSE:ABT) is computed using the system for investing of Louis Navellier and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking ABT has had from Portfolio Grader for the last month.

Currently, Abbott Laboratories (NYSE:ABT) has a Buy using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. ABT has maintained this ranking for the last month.

Portfolio Grader currently ranks Abbott Laboratories (NYSE:ABT) a Buy. Using Louis Navellier's investing system, this analytical tool assesses stocks with fundamental and quantitative metrics. This represents no change from the previous week and is the same ranking ABT has had from Portfolio Grader for the last month.

Portfolio Grader currently ranks Abbott Laboratories (NYSE:ABT) a Buy. Using Louis Navellier's investing approach, this analytical tool researches stocks with fundamental and quantitative analytical tools. ABT has been upgraded from a Hold to a Buy in the last week.

Portfolio Grader currently ranks Abbott Laboratories (NYSE:ABT) a Buy. Using Louis Navellier's investing approach, this analytical tool researches stocks with fundamental and quantitative analytical tools. ABT has been upgraded from a Hold to a Buy in the last week.